FDA Moves to Reassess Hormone Replacement Therapy Warnings

November 10, 2025 - 19:54

In a significant update regarding women's health, FDA Commissioner Dr. Marty Makary announced the agency's plan to eliminate the controversial “black box” warnings associated with hormone replacement therapy (HRT) for menopause. This decision comes in light of new research and insights that challenge the conclusions drawn from the 2002 Women’s Health Initiative study, which previously raised concerns about the safety of HRT.

Dr. Makary emphasized that the FDA is committed to ensuring that women have access to safe and effective treatments for menopausal symptoms. The removal of these warnings is intended to provide clearer guidance to healthcare providers and patients, allowing for informed decision-making without the fear of stigma associated with HRT.

This move is expected to reshape the conversation around menopause management, as many women have been hesitant to pursue HRT due to the longstanding warnings. The FDA's reassessment reflects a growing recognition of the need for balanced information regarding the benefits and risks of hormone therapy in managing menopause symptoms.